News stories about Regeneron Pharmaceuticals (NASDAQ:REGN) have been trending somewhat positive on Monday, according to Accern. Accern scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 48.0469596240771 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
- Edited Transcript of REGN earnings conference call or presentation 2-Aug-18 12:30pm GMT (finance.yahoo.com)
- What Alnylam Pharmaceuticals’ Bottom Line Trend Indicates (finance.yahoo.com)
- Galmed Pharmaceuticals (GLMD) versus Regeneron Pharmaceuticals (REGN) Financial Analysis (americanbankingnews.com)
- NYSE trader: Chip stocks face some serious headwinds, as Morgan Stanley points out (finance.yahoo.com)
- Swinging Stocks: Cisco Systems, Inc. (NASDAQ:CSCO), Newmont Mining Corporation (NYSE:NEM), Regeneron … (thestreetpoint.com)
A number of research firms recently weighed in on REGN. BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 28th. Canaccord Genuity lifted their price objective on shares of Regeneron Pharmaceuticals from $304.00 to $390.00 and gave the company a “hold” rating in a research note on Friday, August 3rd. SunTrust Banks set a $344.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, July 2nd. Morgan Stanley lifted their price objective on shares of Regeneron Pharmaceuticals from $396.00 to $409.00 and gave the company an “equal weight” rating in a research note on Friday, August 3rd. Finally, Robert W. Baird lowered shares of Regeneron Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Friday, August 3rd. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $416.52.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported $5.45 EPS for the quarter, beating analysts’ consensus estimates of $4.60 by $0.85. The firm had revenue of $1.61 billion during the quarter, compared to analyst estimates of $1.56 billion. Regeneron Pharmaceuticals had a net margin of 25.65% and a return on equity of 29.30%. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the previous year, the business earned $4.17 EPS. sell-side analysts forecast that Regeneron Pharmaceuticals will post 18.69 EPS for the current fiscal year.
In other news, Director Joseph L. Goldstein sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, August 2nd. The shares were sold at an average price of $380.00, for a total transaction of $760,000.00. Following the completion of the sale, the director now directly owns 14,000 shares of the company’s stock, valued at approximately $5,320,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman P Roy Vagelos sold 74,670 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, July 10th. The stock was sold at an average price of $367.22, for a total transaction of $27,420,317.40. Following the sale, the chairman now directly owns 553,121 shares of the company’s stock, valued at $203,117,093.62. The disclosure for this sale can be found here. Insiders have sold a total of 286,388 shares of company stock valued at $94,373,982 over the last 90 days. Company insiders own 12.42% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Further Reading: What is the Book Value of a Share?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.